Castle Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Castle Biosciences Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CSTL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001447362
Board of directors
-
Daniel Bradbury · DirectorSince 2023
-
Derek J. Maetzold · Director · Pres. & Chief Exec. OfficerSince 2023
-
Ellen Goldberg · DirectorSince 2023
-
G. Bradley Cole · DirectorSince 2023
-
Kim Caple · DirectorSince 2023
-
Mara G. Aspinall · DirectorSince 2023
-
Miles Harrison · DirectorSince 2023
-
Rodney Cotton · DirectorSince 2024
-
Tiffany Olson · DirectorSince 2023
Board connections
4 of this board's directors also sit on 5 other boards.
- via Daniel Bradbury
- via G. Bradley Cole
- via Tiffany Olson
- via Mara G. Aspinall
- via Daniel Bradbury
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $18,016,834
- 207 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Option exercise | +8,580 | $2.39 | $20,506 |
| Sep 21, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −8,580 | $35.33 | $303,166 |
| Sep 21, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −3,198 | $35.33 | $112,998 |
| Sep 21, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −2,718 | $35.33 | $96,038 |
| Sep 15, 2026 | Juvenal Tobin W Officer (Chief Commercial Officer) | Open-market sale | −3,294 | $35.14 | $115,758 |
| Sep 14, 2026 | Juvenal Tobin W Officer (Chief Commercial Officer) | Open-market sale | −3,306 | $32.32 | $106,863 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Option exercise | +8,584 | $2.39 | $20,516 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −8,361 | $32.00 | $267,552 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −3,124 | $32.00 | $99,968 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −2,656 | $32.00 | $84,992 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −223 | $32.78 | $7,310 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −83 | $32.78 | $2,721 |
| Sep 11, 2026 | Derek J. Maetzold Director, Officer (Pres. & Chief Exec. Officer) | Open-market sale | −71 | $32.78 | $2,327 |
| Sep 1, 2026 | Oelschlager Kristen M Officer (Chief Operating Officer) | Option exercise | +4,152 | $3.38 | $14,034 |
| Sep 1, 2026 | Oelschlager Kristen M Officer (Chief Operating Officer) | Open-market sale | −3,952 | $33.36 | $131,839 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.